Dyne Therapeutics Inc (DYN)
25.58
+0.12
(+0.47%)
USD |
NASDAQ |
Apr 30, 10:27
Dyne Therapeutics Cash from Operations (Quarterly): -35.01M for Dec. 31, 2023
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -35.01M |
| September 30, 2023 | -50.60M |
| June 30, 2023 | -55.64M |
| March 31, 2023 | -46.91M |
| December 31, 2022 | -29.19M |
| September 30, 2022 | -42.80M |
| June 30, 2022 | -30.91M |
| March 31, 2022 | -50.74M |
| Date | Value |
|---|---|
| December 31, 2021 | -28.07M |
| September 30, 2021 | -26.95M |
| June 30, 2021 | -46.15M |
| March 31, 2021 | -18.39M |
| December 31, 2020 | -20.04M |
| September 30, 2020 | -11.89M |
| June 30, 2020 | -7.298M |
| March 31, 2020 | -7.288M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-55.64M
Minimum
Jun 2023
-7.288M
Maximum
Mar 2020
-31.74M
Average
-30.05M
Median
Cash from Operations (Quarterly) Benchmarks
| Solid Biosciences Inc | -20.82M |
| Sana Biotechnology Inc | -51.96M |
| Tenaya Therapeutics Inc | -21.92M |
| Prime Medicine Inc | -43.86M |
| CEL-SCI Corp | -4.888M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 26.20M |
| Cash from Financing (Quarterly) | 0.147M |
| Free Cash Flow | -188.89M |
| Free Cash Flow Per Share (Quarterly) | -0.5714 |
| Free Cash Flow Yield | -12.37% |